Our observations that overactivation of the endogenous STING by an agonist can lead to a small but significant increase in NDD over the already high level due to the BRCA1-deficiency in an ovarian cancer cell line UWB1.289, as well as to a comparatively larger increase in the BRCA1-proficient SKOV-3, are consistent with this notion. This evidence concerns the gene STING1 and ovarian carcinoma.